1-Butanaminium, N,N-dibutyl-N-propyl- | 29814-64-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-Butanaminium, N,N-dibutyl-N-propyl-
• 英文别名: tributyl(propyl)azanium
• CAS: 29814-64-0
• 化学式: C15H34N+
• 分子量: 228.44
• InChiKey: OTMZBTFLNZOUEP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  16
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

文献信息

• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2015113452A1

  公开（公告）日：2015-08-06

  The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

  本发明涉及抑制LRRK2激酶活性的新化合物，其制备方法，含有它们的组合物，以及它们在治疗或预防由LRRK2激酶活性特征的疾病中的应用，例如帕金森病、阿尔茨海默病和肌萎缩侧索硬化症（ALS）。
• [EN] DPP-IV INHIBITORS<br/>[FR] INHIBITEURS DE LA DPP-IV
  申请人：GRAFFINITY PHARMACEUTICALS AG

  公开号：WO2005095343A1

  公开（公告）日：2005-10-13

  The invention relates to compounds of formula (I), Z-C(R<1>R<2>)-C(R<3>NH2)-C(R<4>R<5>)-X-N(R<6>R<7>), wherein Z, R<1-7> and X have the meaning as cited in the description and the claims. Said compounds are useful as DPP-lV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament.

  该发明涉及式(I)的化合物，其中Z-C(R1R2)-C(R3NH2)-C(R4R5)-X-N(R6R7)，其中Z，R1-7和X的含义如描述和权利要求中所述。所述化合物可用作DPP-IV抑制剂。该发明还涉及制备此类化合物以及其作为药物的生产和使用。
• Ionic liquids miscible with various polar/non-polar solvents and method of preparing the same
  申请人：Lim Myong Hoon

  公开号：US20090253924A1

  公开（公告）日：2009-10-08

  Provided are an ionic liquid and a method of preparing the same. The ionic liquid includes at least one type of compound represented by (Cat + )(R′COO − ). Here, the Cat + is a cation selected from the group consisting of quaternary ammonium, quaternary phosphonium, sulfonium, imidazolium, pyridinium, pyrazolium, piperidinium, pyrrolium, pyrrolidinium, triazolium, and a mixture of two or more thereof, and R′ is a hydrocarbon comprising at least one unsaturated bond, and having 4 to 30 carbon atoms. The ionic liquid is partially or completely miscible with various polar and/or non-polar solvents, and may be used as a solvent, a solvent additive, an electrolyte, a heat carrier, a charge carrier, a heat carrier additive, a charge career additive, or a phase transfer catalyst, at room temperatures and below. Furthermore, the cost of manufacturing the ionic liquid can be reduced.

  提供了一种离子液体及其制备方法。该离子液体包括至少一种由(Cat+)(R′COO−)表示的化合物类型。这里，Cat+是从季铵盐、季磷盐、砜、咪唑盐、吡啶盐、吡唑盐、哌啶盐、吡咯盐、吡咯啉盐、三唑盐和两种或更多以上混合物组成的阳离子中选择的，R′是含有至少一条不饱和键的碳氢化合物，具有4至30个碳原子。该离子液体部分或完全与各种极性和/或非极性溶剂相容，并可用作溶剂、溶剂添加剂、电解质、热载体、电荷载体、热载体添加剂、电荷载体添加剂或相转移催化剂，在室温及以下温度下使用。此外，可以降低制造该离子液体的成本。
• DPP-IV inhibitors
  申请人：Santhera Pharmaceuticals (Schweiz) GmbH

  公开号：EP1702916A1

  公开（公告）日：2006-09-20

  The invention relates to compounds of formula (I) wherein Z, R1-7, X and n have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament.

  该发明涉及式(I)的化合物，其中Z、R1-7、X和n的含义如描述和权利要求中所述。所述化合物可用作DPP-IV抑制剂。该发明还涉及制备这种化合物以及其作为药物的生产和使用。
• Dpp-Iv Inhibitors
  申请人：Edwards Paul John

  公开号：US20080275086A1

  公开（公告）日：2008-11-06

  The invention relates to compounds of formula (I) wherein Z, R 1-7 , X and n have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament.

  本发明涉及公式（I）的化合物，其中Z，R1-7，X和n的含义如描述和权利要求所述。所述化合物可用作DPP-IV抑制剂。本发明还涉及制备这种化合物以及作为药物的生产和使用。